» Articles » PMID: 36130500

Genome-wide Fetalization of Enhancer Architecture in Heart Disease

Abstract

Heart disease is associated with re-expression of key transcription factors normally active only during prenatal development of the heart. However, the impact of this reactivation on the regulatory landscape in heart disease is unclear. Here, we use RNA-seq and ChIP-seq targeting a histone modification associated with active transcriptional enhancers to generate genome-wide enhancer maps from left ventricle tissue from up to 26 healthy controls, 18 individuals with idiopathic dilated cardiomyopathy (DCM), and five fetal hearts. Healthy individuals have a highly reproducible epigenomic landscape, consisting of more than 33,000 predicted heart enhancers. In contrast, we observe reproducible disease-associated changes in activity at 6,850 predicted heart enhancers. Combined analysis of adult and fetal samples reveals that the heart disease epigenome and transcriptome both acquire fetal-like characteristics, with 3,400 individual enhancers sharing fetal regulatory properties. We also provide a comprehensive data resource (http://heart.lbl.gov) for the mechanistic exploration of DCM etiology.

Citing Articles

Epigenetics of cardiomyopathies: the next frontier.

Hajdarpasic A, Tukker M, Rijdt W, Mohamedhoesein S, Meijers W, Caliskan K Heart Fail Rev. 2024; 30(1):257-270.

PMID: 39586986 PMC: 11646213. DOI: 10.1007/s10741-024-10460-4.


A gene desert required for regulatory control of pleiotropic Shox2 expression and embryonic survival.

Abassah-Oppong S, Zoia M, Mannion B, Rouco R, Tissieres V, Spurrell C Nat Commun. 2024; 15(1):8793.

PMID: 39389973 PMC: 11467299. DOI: 10.1038/s41467-024-53009-7.


Mutagenesis Sensitivity Mapping of Human Enhancers .

Kosicki M, Zhang B, Pampari A, Akiyama J, Plajzer-Frick I, Novak C bioRxiv. 2024; .

PMID: 39282388 PMC: 11398460. DOI: 10.1101/2024.09.06.611737.


Assessing the impact of transcriptomics data analysis pipelines on downstream functional enrichment results.

Paton V, Ramirez Flores R, Gabor A, Badia-I-Mompel P, Tanevski J, Garrido-Rodriguez M Nucleic Acids Res. 2024; 52(14):8100-8111.

PMID: 38943333 PMC: 11317128. DOI: 10.1093/nar/gkae552.


Dynamic enhancer landscapes in human craniofacial development.

Rajderkar S, Paraiso K, Amaral M, Kosicki M, Cook L, Darbellay F Nat Commun. 2024; 15(1):2030.

PMID: 38448444 PMC: 10917818. DOI: 10.1038/s41467-024-46396-4.


References
1.
Pei J, Harakalova M, Treibel T, Lumbers R, Boukens B, Efimov I . H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts. Clin Epigenetics. 2020; 12(1):106. PMC: 7362435. DOI: 10.1186/s13148-020-00895-5. View

2.
Norton N, Robertson P, Rieder M, Zuchner S, Rampersaud E, Martin E . Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era. Circ Cardiovasc Genet. 2012; 5(2):167-74. PMC: 3332064. DOI: 10.1161/CIRCGENETICS.111.961805. View

3.
Dickel D, Barozzi I, Zhu Y, Fukuda-Yuzawa Y, Osterwalder M, Mannion B . Genome-wide compendium and functional assessment of in vivo heart enhancers. Nat Commun. 2016; 7:12923. PMC: 5059478. DOI: 10.1038/ncomms12923. View

4.
Pennacchio L, Ahituv N, Moses A, Prabhakar S, Nobrega M, Shoukry M . In vivo enhancer analysis of human conserved non-coding sequences. Nature. 2006; 444(7118):499-502. DOI: 10.1038/nature05295. View

5.
Tan F, Moravec C, Li J, Apperson-Hansen C, McCarthy P, Young J . The gene expression fingerprint of human heart failure. Proc Natl Acad Sci U S A. 2002; 99(17):11387-92. PMC: 123266. DOI: 10.1073/pnas.162370099. View